Clinical Trial

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

Study acronym: PREDICT-1
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.
Protocol Amendment History 1 change
notable Trial sites expanded: 10 -> 14 locations 2026-05-30
Trial Details
NCT Number NCT07548632
Lead Sponsor Oculis
Conditions Dry Eye Disease (DED)
Enrollment 160 participants
Start Date 2026-04-16
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-06